Charles River Laboratories International Inc
CRL195.985USD
+0.765+0.39%
Handelsschluss 12/17, 16:00（ET）Kurse um 15 Minuten verzögert
9.65BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Charles River Laboratories International Inc Unternehmen
Charles River Laboratories International, Inc. is a drug development company. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.
Charles River Laboratories International Inc Informationen
BörsenkürzelCRL
Name des UnternehmensCharles River Laboratories International Inc
IPO-datumJun 23, 2000
CEOFoster (James C)
Anzahl der mitarbeiter18600
WertpapierartOrdinary Share
GeschäftsjahresendeJun 23
Addresse251 Ballardvale St
StadtWILMINGTON
BörseNASDAQ OMX NASDAQ Basic NYSE
LandUnited States of America
Postleitzahl01887
Telefon17812226000
Websitehttps://www.criver.com/
BörsenkürzelCRL
IPO-datumJun 23, 2000
CEOFoster (James C)
Führungskräfte von Charles River Laboratories International Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. James C. Foster
Mr. James C. Foster
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
267.96K
+6.88%
Ms. Birgit Girshick
Ms. Birgit Girshick
Chief Operating Officer, Corporate Executive Vice President
Chief Operating Officer, Corporate Executive Vice President
57.72K
+24.38%
Ms. Victoria L. (Vicky) Creamer
Ms. Victoria L. (Vicky) Creamer
Corporate Executive Vice President, Chief People Officer
Corporate Executive Vice President, Chief People Officer
17.89K
+48.67%
Ms. Shannon M. Parisotto
Ms. Shannon M. Parisotto
Corporate Executive Vice President - Discovery and Safety Assessment
Management
Corporate Executive Vice President - Discovery and Safety Assessment
Management
12.88K
+69.56%
Mr. Joseph W. LaPlume
Mr. Joseph W. LaPlume
Corporate Executive Vice President - Corporate Development and Strategy
Corporate Executive Vice President - Corporate Development and Strategy
12.48K
-8.77%
Ms. Virginia M. (Gina) Wilson, CPA
Ms. Virginia M. (Gina) Wilson, CPA
Independent Director
Independent Director
4.91K
+23.86%
Dr. Nancy C. Andrews, M.D., Ph.D.
Dr. Nancy C. Andrews, M.D., Ph.D.
Independent Director
Independent Director
3.96K
+31.35%
Ms. Reshema Kemps-Polanco
Ms. Reshema Kemps-Polanco
Independent Director
Independent Director
2.59K
+155.42%
Dr. Craig B. Thompson, M.D.
Dr. Craig B. Thompson, M.D.
Independent Director
Independent Director
2.41K
+64.49%
Mr. Abraham N. (Abe) Ceesay
Mr. Abraham N. (Abe) Ceesay
Independent Director
Independent Director
946.00
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. James C. Foster
Mr. James C. Foster
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
267.96K
+6.88%
Ms. Birgit Girshick
Ms. Birgit Girshick
Chief Operating Officer, Corporate Executive Vice President
Chief Operating Officer, Corporate Executive Vice President
57.72K
+24.38%
Ms. Victoria L. (Vicky) Creamer
Ms. Victoria L. (Vicky) Creamer
Corporate Executive Vice President, Chief People Officer
Corporate Executive Vice President, Chief People Officer
17.89K
+48.67%
Ms. Shannon M. Parisotto
Ms. Shannon M. Parisotto
Corporate Executive Vice President - Discovery and Safety Assessment
Management
Corporate Executive Vice President - Discovery and Safety Assessment
Management
12.88K
+69.56%
Mr. Joseph W. LaPlume
Mr. Joseph W. LaPlume
Corporate Executive Vice President - Corporate Development and Strategy
Corporate Executive Vice President - Corporate Development and Strategy
12.48K
-8.77%
Ms. Virginia M. (Gina) Wilson, CPA
Ms. Virginia M. (Gina) Wilson, CPA
Independent Director
Independent Director
4.91K
+23.86%
Umsatzaufteilung
Währung: USDAktualisiert: Mon, Oct 6
Währung: USDAktualisiert: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
FY2015
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
DSA
618.03M
59.88%
RMS
213.27M
20.66%
Manufacturing
200.84M
19.46%
Nach RegionUSD
Name
Umsatz
Anteil
United States
549.86M
53.27%
Europe
281.86M
27.31%
Canada
135.59M
13.14%
Asia Pacific (Region)
54.50M
5.28%
Other
10.33M
1.00%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
DSA
618.03M
59.88%
RMS
213.27M
20.66%
Manufacturing
200.84M
19.46%
Aktionärsstatistik
Aktualisiert: Sun, Nov 16
Aktualisiert: Sun, Nov 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
11.84%
Wellington Management Company, LLP
6.48%
BlackRock Institutional Trust Company, N.A.
5.73%
Allspring Global Investments, LLC
4.43%
State Street Investment Management (US)
3.72%
Andere
67.80%
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
11.84%
Wellington Management Company, LLP
6.48%
BlackRock Institutional Trust Company, N.A.
5.73%
Allspring Global Investments, LLC
4.43%
State Street Investment Management (US)
3.72%
Andere
67.80%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
44.49%
Investment Advisor
44.48%
Hedge Fund
7.70%
Research Firm
4.24%
Bank and Trust
3.01%
Pension Fund
1.52%
Individual Investor
1.06%
Sovereign Wealth Fund
1.04%
Insurance Company
0.08%
Institutionelle Beteiligung
Aktualisiert: Mon, Dec 8
Aktualisiert: Mon, Dec 8
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
1367
52.25M
129.09%
+28.56K
2025Q3
1413
52.22M
129.54%
+64.86K
2025Q2
1411
52.12M
127.74%
-2.86M
2025Q1
1414
54.69M
123.53%
-5.98M
2024Q4
1410
54.25M
114.75%
+1.17M
2024Q3
1372
53.38M
114.53%
-33.66K
2024Q2
1378
53.46M
111.45%
+347.48K
2024Q1
1371
53.18M
111.09%
-4.05M
2023Q4
1405
52.96M
112.24%
-202.82K
2023Q3
1421
52.99M
111.08%
+631.82K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
5.80M
11.79%
-293.30K
-4.81%
Jun 30, 2025
Wellington Management Company, LLP
3.77M
7.66%
-517.21K
-12.07%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.75M
5.59%
-156.85K
-5.39%
Jun 30, 2025
Allspring Global Investments, LLC
2.29M
4.66%
+516.52K
+29.11%
Jun 30, 2025
State Street Investment Management (US)
1.86M
3.78%
-43.84K
-2.30%
Jun 30, 2025
Ariel Investments, LLC
1.42M
2.88%
+314.57K
+28.58%
Jun 30, 2025
Harris Associates L.P.
1.16M
2.36%
+1.16M
--
Jun 30, 2025
Geode Capital Management, L.L.C.
1.23M
2.5%
-31.43K
-2.49%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
1.01M
2.05%
+148.44K
+17.22%
Jun 30, 2025
Invesco Capital Management LLC
1.09M
2.22%
+110.27K
+11.23%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
Invesco S&P 500 Equal Weight Health Care ETF
1.92%
Schwab Ariel Opportunities ETF
1.82%
iShares Health Innovation Active ETF
1.74%
First Trust NASDAQ Pharmaceuticals ETF
1.71%
ROBO Global Healthcare Technology & Innovation ETF
1.69%
VanEck Biotech ETF
1.44%
Franklin Genomic Advancements ETF
1.42%
WisdomTree US Value Fund
1.15%
Invesco S&P 500 High Beta ETF
1.14%
Pacer Lunt Large Cap Alternator ETF
0.97%
Mehr Anzeigen
Invesco S&P 500 Equal Weight Health Care ETF
Anteil1.92%
Schwab Ariel Opportunities ETF
Anteil1.82%
iShares Health Innovation Active ETF
Anteil1.74%
First Trust NASDAQ Pharmaceuticals ETF
Anteil1.71%
ROBO Global Healthcare Technology & Innovation ETF
Anteil1.69%
VanEck Biotech ETF
Anteil1.44%
Franklin Genomic Advancements ETF
Anteil1.42%
WisdomTree US Value Fund
Anteil1.15%
Invesco S&P 500 High Beta ETF
Anteil1.14%
Pacer Lunt Large Cap Alternator ETF
Anteil0.97%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Charles River Laboratories International Inc?
Die fünf größten Anteilseigner von Charles River Laboratories International Inc sind:
The Vanguard Group, Inc. hält 5.80M Aktien, was 11.79% der Gesamtaktien entspricht.
Wellington Management Company, LLP hält 3.77M Aktien, was 7.66% der Gesamtaktien entspricht.
BlackRock Institutional Trust Company, N.A. hält 2.75M Aktien, was 5.59% der Gesamtaktien entspricht.
Allspring Global Investments, LLC hält 2.29M Aktien, was 4.66% der Gesamtaktien entspricht.
State Street Investment Management (US) hält 1.86M Aktien, was 3.78% der Gesamtaktien entspricht.
The Vanguard Group, Inc. hält 5.80M Aktien, was 11.79% der Gesamtaktien entspricht.
Wellington Management Company, LLP hält 3.77M Aktien, was 7.66% der Gesamtaktien entspricht.
BlackRock Institutional Trust Company, N.A. hält 2.75M Aktien, was 5.59% der Gesamtaktien entspricht.
Allspring Global Investments, LLC hält 2.29M Aktien, was 4.66% der Gesamtaktien entspricht.
State Street Investment Management (US) hält 1.86M Aktien, was 3.78% der Gesamtaktien entspricht.
Was sind die drei wichtigsten Anteilseigner-Typen von Charles River Laboratories International Inc?
Die drei wichtigsten Anteilseigner-Typen von Charles River Laboratories International Inc sind:
The Vanguard Group, Inc.
Wellington Management Company, LLP
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Wellington Management Company, LLP
BlackRock Institutional Trust Company, N.A.
Wie viele Institutionen halten Anteile an Charles River Laboratories International Inc (CRL)?
Mit Stand vom 2025Q4 halten 1367 Institutionen Anteile an Charles River Laboratories International Inc, mit einem Gesamtmarktwert von etwa 52.25M, was 129.09% der Gesamtanteile entspricht. Im Vergleich zum 2025Q3 ist der institutionelle Aktienbesitz um -0.45% gestiegen.
Was ist die größte Einnahmequelle von Charles River Laboratories International Inc?
Am FY2025Q2 erzielte das Geschäft mit DSA für Charles River Laboratories International Inc den höchsten Umsatz in Höhe von 618.03M, was 59.88% des Gesamtumsatzes entspricht.
